Oppenheimer Trims Gilead Sciences Price Targetby Mark Eisenberg 12.02.2024Oppenheimer lowers price target on Gilead Sciences after Q4 earnings report and challenges in drug pipeline. Optimistic about prospects for ...
Atossa Genetics: Potential Breakthrough in Breast Cancer?by Lilu Anderson 12.02.2024Biopharmaceutical company Atossa Genetics receives Buy rating from H.C. Wainwright, with a new price target of $4.00. The company's promising ...
European GRANOLAS Stocks Outpace Tech Giantsby Mark Eisenberg 12.02.2024European companies known as GRANOLAS have proven to be a lower-risk investment, matching the growth of highflying tech giants. With ...
Asian Stocks Stagnate, Eyes on Fed Insightsby Mark Eisenberg 12.02.2024Asian stocks traded in a narrow range due to many major markets being closed for Chinese New Year. Australian market ...
CSL Shares Plunge Amid Failed Heart Drug Trialby Mark Eisenberg 12.02.2024Shares of pharmaceutical firm CSL are set for their worst day in four months as the company announced disappointing results ...
New Tech Tracks Brain Cells’ Off Switchesby Lilu Anderson 23.01.2024Scientists at Scripps Research have developed a breakthrough technology that allows them to track when brain cells shut off, providing ...
From Sage Therapeutics to Venture Capital: Biotech’s Shifting Landscapeby Mark Eisenberg 08.01.2024Cure Ventures hires executives from Sage Therapeutics, showcasing the growing interest in neuroscience startups and the potential for advancements in ...
Johnson & Johnson vs. Pfizer: Pharmaceutical Industry SWOTby Mark Eisenberg 21.08.2023The competition between Johnson & Johnson and Pfizer in the pharmaceutical industry is heating up. Here's a SWOT analysis of ...